OB 318

Drug Profile

OB 318

Alternative Names: OB-318

Latest Information Update: 26 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oneness Biotech
  • Class Anti-inflammatories; Antineoplastics; Herbal medicines; Traditional-Chinese-medicine
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; Proto oncogene protein c-akt inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatocellular carcinoma

Most Recent Events

  • 28 Apr 2016 Phase-I clinical trials in Hepatocellular carcinoma in Taiwan (PO) before April 2016
  • 28 Apr 2016 Phase-I clinical trials in Hepatocellular carcinoma in USA (PO) before April 2016
  • 02 Dec 2015 Oneness Biotech receives patent allowance for OB318 in Europe, Taiwan, Japan and China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top